[Diagnosis of Hereditary Tumors Using Multi Gene Panel Testing(MGPT)-Current Status and Issues in Japan or Worldwide]

Pathogenic variant carriers of hereditary tumors have the risk of developing cancer in multiple organs, and genetic testing can be used as an opportunity to conduct surveillance for early detection of cancer and to prevent the development of new cancers and it becomes possible to develop individualized preventive strategies including risk-reductive surgery. Multi gene panel testing(MGPT), which simultaneously measures several dozen to more than 100 genes, has been widely used to diagnose of hereditary tumors in worldwide since around 2014. Although, MGPTs has not been approved under the Pharmaceutical and Medical Devices Act in Japan. MGPTs for hereditary tumors can be expected to become the mainstream of diagnosis for hereditary tumors in near future.